| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H13BrN2O6 |
| Molecular Weight | 349.135 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=C(\C=C\Br)C(=O)NC2=O
InChI
InChIKey=GCQYYIHYQMVWLT-HQNLTJAPSA-N
InChI=1S/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8+,10-/m1/s1
| Molecular Formula | C11H13BrN2O6 |
| Molecular Weight | 349.135 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
PubMed
Patents
Sample Use Guides
for mice: 5% BV-araU (SORIVUDINE) cream given 4 times daily for 5 days starting 1 day after inoculation
Route of Administration:
Topical
The inhibitory effect of BV-araU (SORIVUDINE) on DNA synthesis in human embryonic lung cells infected with varicella-zoster virus (VZV) or herpes simplex virus type 1 (HSV-1) was compared with that of acyclovir. he inhibitory concentration of BV-araU for DNA synthesis in VZV-infected cells was one-thousandth of that of acyclovir.
